Stryker (SYK) DIvidends Date & History

Key Takeaways

• Stryker pays a quarterly dividend of $0.88 per share, translating to an annual dividend of $3.52 and a dividend yield of approximately 1.08%.
• The company has raised its dividend for 32 consecutive years, placing it among the Dividend Champions — a rare group of companies with multi-decade payout growth streaks.
• With a payout ratio of roughly 40% and strong free cash flow coverage, the dividend sits on a solid and sustainable foundation.
• The five-year dividend growth rate stands at approximately 7.6% annually, outpacing inflation and reinforcing the company's commitment to returning capital to shareholders.
• Stryker's dividend yield is below the medical device industry average, making it more suitable for dividend growth investors than those seeking high current income.

Dividend Overview

Stryker Corporation (SYK), one of the world's largest medical technology companies, pays a quarterly dividend of $0.88 per share, which equates to an annual dividend of $3.52. At recent share prices, the dividend yield is approximately 1.08%. Dividends are distributed quarterly, with the most recent ex-dividend date falling on June 30, 2026, and the corresponding payment date on July 31, 2026. Stryker is not a high-yield stock — its yield sits below both the broader healthcare sector average and the overall S&P 500 average. Instead, Stryker is best characterized as a dividend growth stock: a company with a modest current yield that prioritizes consistent, above-inflation annual increases over maximizing immediate payouts. For investors focused on long-term compounding and rising income streams, this profile carries meaningful appeal.

Dividend History and Growth

Stryker has been paying dividends to shareholders since 1991 and has increased its dividend every year for 32 consecutive years. This streak places the company among the elite Dividend Champions, a designation reserved for companies with at least 25 consecutive years of dividend increases. Over the past five years, Stryker's dividend has grown at an average annual rate of approximately 7.6%, while the 10-year growth rate stands near 9.5%. The annual dividend has climbed from $2.59 per share in 2021 to $3.52 per share on a trailing basis. In early 2026, the board approved a quarterly increase from $0.84 to $0.88 per share, representing a 4.8% year-over-year raise. Stryker has never cut its dividend, and there is no indication in the company's history of a reduction, reflecting a management philosophy that treats the dividend as a durable, steadily rising obligation.

Dividend Sustainability and Payout Ratio

Stryker's dividend is well-supported by earnings and cash flow. The payout ratio based on earnings per share (EPS) stands at approximately 40%, which means the company retains 60% of its earnings for reinvestment in research and development, acquisitions, and debt management. On a free cash flow basis, the payout ratio is even lower, estimated at roughly 29%, reflecting the fact that Stryker generates significantly more cash than its accounting earnings suggest. In the trailing twelve-month period, the company reported operating cash flow of $5.04 billion and free cash flow of $4.17 billion against annual dividend obligations of approximately $1.3 billion. The debt-to-equity ratio sits at a manageable 0.64, and the company's revenue base — exceeding $25 billion — is diversified across multiple segments including MedSurg and Neurotechnology, and Orthopaedics. The combination of ample free cash flow, a moderate payout ratio, and manageable leverage provides a wide margin of safety around the dividend.

Dividend Compared to Industry Peers

Within the medical device and broader healthcare equipment industry, Stryker's dividend yield of approximately 1.08% sits below the sector average. For context, peers such as JNJ (Johnson & Johnson) and MDT (Medtronic) offer yields in the 3% range, while ABT (Abbott Laboratories) yields around 1.9%. However, Stryker's dividend growth rate is competitive with or exceeds many of these peers. Additionally, some competitors such as BSX (Boston Scientific) pay no dividend at all, choosing instead to reinvest all earnings into the business. Stryker occupies a middle ground: it offers a lower current yield than income-heavy peers but compensates with faster dividend growth and an exceptionally reliable track record of increases. This profile aligns most closely with companies that prioritize total shareholder return through a balanced approach of reinvestment, dividend growth, and occasional share repurchases.

AI Screener

For investors seeking to identify dividend-paying stocks, growth opportunities, or technical breakout candidates across the market, Tickeron's AI Screener offers a powerful AI-driven discovery platform. The AI Screener allows users to filter thousands of stocks and exchange-traded funds (ETFs) using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility metrics, and fundamental data. Whether you are searching for reliable dividend stocks like Stryker, high-momentum names, or undervalued sectors, the screener streamlines the research process by surfacing relevant opportunities quickly and efficiently. By leveraging artificial intelligence to scan and rank securities based on user-defined parameters, the AI Screener helps traders and investors move from broad market views to actionable insights faster than traditional manual screening methods.

Is This Stock Attractive for Dividend Investors?

Stryker is best suited for dividend growth investors and long-term, total-return-oriented investors rather than those who prioritize high current income. A yield of approximately 1.08% will not satisfy investors seeking immediate cash flow, but the combination of a 32-year dividend growth streak, a 7.6% five-year growth rate, and strong free cash flow coverage makes the stock compelling for those with a multi-year to multi-decade investment horizon. Conservative investors may appreciate the low payout ratio and the defensive nature of the medical technology industry, which benefits from aging demographics and rising global healthcare demand. The dividend, while modest today, has the potential to compound meaningfully over time — especially if Stryker continues its historical pattern of mid-to-high single-digit annual increases. That said, investors who require a yield above 3% to meet income needs will likely find more suitable candidates elsewhere in the healthcare sector. Stryker is a quality compounder, not an income vehicle, and its dividend strategy reflects that reality.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations